Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients*

OBJECTIVES: Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Crit Care Med
Auteurs principaux: Schlosser, Kenny, Wang, Jia-Pey, dos Santos, Claudia, Walley, Keith R., Marshall, John, Fergusson, Dean A., Winston, Brent W., Granton, John, Watpool, Irene, Stewart, Duncan J., McIntyre, Lauralyn A., Mei, Shirley H. J.
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2019
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6629173/
https://ncbi.nlm.nih.gov/pubmed/30720538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000003657
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires